Prediction and Study of Anticonvulsant Properties of Benzimidazole Derivatives
Anticonvulsive activities of some condensed imidazo[1,2-a]benzimidazole derivatives were predicted using PASS software. Benzimidazoles as a class showed promise as sources of anticonvulsants. Several compounds demonstrated various levels of anticonvulsive activity in the corazole-induced seizure model (75 mg/kg, s.c.). The most promising compounds (laboratory codes RU-1205, RU-285, RU-1204, and RU-1203) at a dose of 10 mg/kg (i.p.) showed high levels of anticonvulsive activity comparable with that of reference valproic acid (130 mg/kg, i.p.) at a molar ratio of ~1:30. The Free—Wilson model was used to describe quantitative structure—activity relationships in order to evaluate contributions of substituents or structural fragments to the anticonvulsive activity of the parent structure. Four pharmacophore patterns that favored high anticonvulsive activity among imidazo[1, 2-a]benzimidazole derivatives were found using IT Microcosm.
Keywordsbenzimidazole corazole screening anticonvulsive activity anticonvulsants valproic acid epilepsy PASS system IT Microcosm Free—Wilson method pharmacophores
The synthesis of the chemical compounds was sponsored by the project part of a state task for scientific activity (No. 4.196.2014/K) and was performed using equipment at the Molecular Spectroscopy CCU, SFU. Activities were predicted using PASS within the framework of the Basic Research Program of State Academies of Sciences for 2014 – 2020 (Topic No. 3).
- 1.M. J. Brodie, S. C. Schachter, and P. K. L. Kwan, Fast Facts: Epilepsy, Health Press, Albuquerque, New Mexico, USA (2012).Google Scholar
- 4.D. Pathak, N. Siddiqui, B. Bhrigu, et al., Pharm. Lett., 2(2), 27 – 34 (2010).Google Scholar
- 6.T. V. Gamma, I. I. Korenyuk, and D. R. Khusainov, Neuro- and Psychotropic Effects of Benzimidazole and Its Derivatives [in Russian], Lambert Academic Publishing, Saarbrucken (2012), pp. 46 – 80.Google Scholar
- 8.K. Yu. Kalitin, O. Yu. Grechko, A. A. Spasov, and V. A. Anisimova, Eksp. Klin. Farmakol., 78(4), 3 – 5 (2015).Google Scholar
- 9.A. A. Spasov, K. Yu. Kalitin, O. Yu. Grechko, and V. A. Anisimova, Byull. Eksp. Biol. Med., 160(9), 320 (2015).Google Scholar
- 11.V. A. Anisimova, A. A. Spasov, V. A. Kosolapov, et al., Khim.-farm. Zh., 39(9), 26 – 32 (2005); Pharm. Chem. J., 39(9), 476 – 483 (2005).Google Scholar
- 13.URL www.way2drug.com/passonlineGoogle Scholar
- 14.A. N. Mironov (ed.), Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow (2012), pp. 235 – 250.Google Scholar
- 15.J. J. Luszczki, J. Pre-Clin. Clin. Res., 2(1), 40 – 45 (2008).Google Scholar
- 17.P. M. Vassiliev, A. A. Spasov, V. A. Kosolapov, et al., in: Application of Computational Techniques in Pharmacy and Medicine, L. Gorb, V. Kuz’min, and E. Muratov (eds.), Challenges and Advances in Computational Chemistry and Physics 17, J. Leszczynski (ed.), Springer Science+Business Media, Dordrecht (2014), pp. 369 – 431, 550.Google Scholar
- 18.B. Bhrigu, N. Siddiqui, D. Pathak, et al., Acta Pol. Pharm. Drug Res., 69(1), 53 – 62 (2012).Google Scholar
- 19.G. Akula, B. Srinivas, M. Vidyasagar, et al., Int. J. PharmTech Res., 3, 360 – 364 (2011).Google Scholar